Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Non-Small Cell Lung Cancer News

News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways

Advertisement

FDA Approval
FDA Approves Osimertinib Plus Platinum-Based Chemotherapy For Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
02/21/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 FLAURA 2 trial, the FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R...
Based on results from the phase 3 FLAURA 2 trial, the FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R...
Based on results from the phase...
02/21/2024
Oncology
News
Addition of Canakinumab to First-Line Pembrolizumab Plus Chemotherapy Did Not Prolong Survival Outcomes Among Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
01/09/2024

Stephanie Holland 

Stephanie Holland 
According to results from the CANOPY-1 trial, the addition of canakinumab to first-line pembrolizumab plus chemotherapy did not prolong PFS or OS among patients with advanced or metastatic non-small cell lung cancer who do not harbor ALK or...
According to results from the CANOPY-1 trial, the addition of canakinumab to first-line pembrolizumab plus chemotherapy did not prolong PFS or OS among patients with advanced or metastatic non-small cell lung cancer who do not harbor ALK or...
According to results from the...
01/09/2024
Oncology
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023

Grace Taylor

Grace Taylor
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways

Advertisement

News
New Dimensions in Comprehensive Genomic Testing
10/17/2023

Grace Taylor

Grace Taylor
Eric Severson, MD, PhD, Labcorp Oncology, examines genomic testing’s role in comprehensive oncology pathways.
Eric Severson, MD, PhD, Labcorp Oncology, examines genomic testing’s role in comprehensive oncology pathways.
Eric Severson, MD, PhD, Labcorp...
10/17/2023
Journal of Clinical Pathways
News
Exploring Efficacy and Safety of Second-Line Chemotherapy in Advanced NSCLC With Interstitial Lung Disease
10/07/2022

Yvette C Terrie

Yvette C Terrie
A recent study found that second-line chemotherapy among patients with NSCLC complicated by interstitial lung disease (ILD) has a certain effectiveness, but some patients may experience harsh adverse effects of ILD.
A recent study found that second-line chemotherapy among patients with NSCLC complicated by interstitial lung disease (ILD) has a certain effectiveness, but some patients may experience harsh adverse effects of ILD.
A recent study found that...
10/07/2022
Journal of Clinical Pathways
News
Score Model for Prediction and Prognosis of Patients With Advanced NSCLC Treated With Nivolumab or Pembrolizumab
09/27/2022

Yvette C Terrie

Yvette C Terrie
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.
Findings from a study provide...
09/27/2022
Journal of Clinical Pathways

Advertisement

News
Impact of Nursing Model Based on Self-Efficacy and Cognition of Life Meaning in Patients with NSCLC
09/01/2022

Yvette C Terrie

Yvette C Terrie
Nursing model intervention established on Rosenthal effect may improve the self-efficacy and meaning of life in patients with non-small cell lung cancer, and diminish the negative emotions and self-burden.
Nursing model intervention established on Rosenthal effect may improve the self-efficacy and meaning of life in patients with non-small cell lung cancer, and diminish the negative emotions and self-burden.
Nursing model intervention...
09/01/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use